• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors May Respond To BioCryst (BCRX) Hiring Its First CSO To Drive Rare-Disease Deals

    Simply Wall St·07/23/2026 08:26:59
    Listen to the news
    • In July 2026, BioCryst Pharmaceuticals, Inc. appointed David W. Jenkins, MA, PhD, as its first Chief Scientific Officer, reporting to Chief Research and Development Officer Dr. Sandeep Menon to build and lead a research team focused on external innovation and partnerships in rare disease therapies.
    • By creating a new CSO role and hiring an executive with extensive external innovation experience from companies like Ipsen, Novartis and AstraZeneca, BioCryst is signaling a deeper commitment to expanding its rare disease pipeline through both internal research and partnered assets.
    • We’ll now examine how installing a new Chief Scientific Officer focused on external innovation could reshape BioCryst’s rare disease investment narrative.

    Capitalize on the AI infrastructure supercycle with our selection of the 54 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

    BioCryst Pharmaceuticals Investment Narrative Recap

    To own BioCryst, you need to believe ORLADEYO can keep funding a broader rare disease portfolio while new assets gradually reduce single‑drug dependence. The Jenkins CSO hire supports that long term pipeline goal, but it does not materially change the near term focus on ORLADEYO execution and upcoming data from early programs, nor the key risk that heavy R&D and business development spending may not translate into commercially viable therapies.

    The recent license agreement granting Neopharmed Gentili rights to navenibart in Europe is closely tied to this external innovation push. While Jenkins concentrates on sourcing and shaping future rare disease assets, the navenibart deal already shows BioCryst working with partners to turn its science into non‑US revenue streams, which could modestly diversify away from ORLADEYO if future milestones and royalties are realized.

    Yet even with these developments, investors should be aware that the company’s heavy reliance on ORLADEYO leaves it exposed if...

    Read the full narrative on BioCryst Pharmaceuticals (it's free!)

    BioCryst Pharmaceuticals' narrative projects $930.1 million revenue and $131.3 million earnings by 2029. This requires 1.6% yearly revenue growth and a $589.3 million earnings increase from -$458.0 million today.

    Uncover how BioCryst Pharmaceuticals' forecasts yield a $21.30 fair value, a 124% upside to its current price.

    Exploring Other Perspectives

    BCRX 1-Year Stock Price Chart
    BCRX 1-Year Stock Price Chart

    While consensus focuses on ORLADEYO and measured pipeline progress, the most optimistic analysts once modeled about US$1.0 billion revenue and US$346.0 million earnings by 2029, so Jenkins’ external innovation remit could either reinforce that diversification story or highlight how uncertain long term pipeline expansion really is.

    Explore 4 other fair value estimates on BioCryst Pharmaceuticals - why the stock might be worth just $21.00!

    Reach Your Own Conclusion

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Want Some Alternatives?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.